Differences in the expression of SSTR1–5 in meningiomas and its therapeutic potential

Felix Behling1,2,3 · Christina Fodi1,2,3 · Marco Skardelly1,2,3 · Mirjam Renovanz1,2,3,4 · Salvador Castaneda2,3,5 · Ghazaleh Tabatabai1,2,3,4,6,7 · Jürgen Honegger1,2,3 · Marcos Tatagiba1,2,3 · Jens Schittenhelm2,3,8

Received: 3 March 2021 / Revised: 3 April 2021 / Accepted: 15 April 2021 / Published online: 26 April 2021 © The Author(s) 2021

Abstract
Beyond microsurgical resection and radiation therapy, there are currently no established treatment alternatives for meningioma patients. In selected cases, peptide radio receptor therapy (PRRT) can be implemented. For this purpose, a radionuclide is bound to a substance targeting specific receptors in meningiomas. One of them is somatostatin receptor 2, which can be found in most meningiomas. However, other somatostatin receptors (SSTR) exist, but their expressions have only been described in small case series. In this study, we analyzed the expression of SSTR1, 2A, 3, 4, and 5 in a large cohort of meningiomas in order to enable further refinement of this innovative treatment option. Overall, 726 tumor samples were processed into tissue microarrays and stained for SSTR1, 2A, 3, 4, and 5 immunohistochemically. Microscopic evaluation was done with an established semiquantitative score regarding percentual quantification and staining intensity, and results were correlated with clinical data. There was a significant lower rate of SSTR1 expression in meningiomas of male patients. Older age was associated with higher expression of SSTR1, 2A, and 5 and lower scores for SSTR3 and 4. Tumors treated with radiotherapy before resection showed lower rates of SSTR1 and 5 expression, while recurrent meningiomas had lower SSTR1 scores. Tumor tissue from patients suffering from neurofibromatosis type 2 had lower expression scores for SSTR1, 2, and 5. For SSTR3 and 4, NF2 patients showed higher scores than sporadic tumors. Spinal meningiomas had higher scores for SSTR1, 4, and 5 compared tumor location of the skull base and convexity/falx. Overall, higher WHO grade was associated with lower SSTR scores. While all SSTRs were expressed, there are marked differences of SSTR expression between meningioma subgroups. This has the potential to drive the development of more selective PRRT substances with higher treatment efficacy.

Keywords Meningioma · Somatostatin receptor · Peptide receptor radionuclide therapy (PRRT) · Neurofibromatosis · Immunohistochemistry · Tissue microarray
Introduction

Meningioma is the most common benign intracranial neoplasm. It represents 36% of all central nervous system tumors with only 1.3% showing malignant features [29]. If a meningioma causes symptoms, it shows significant growth or has reached a critical size; treatment is required [15]. In most cases, patients can be cured by radical surgical resection [35]. Radiation is also a primary treatment option in selected cases and plays a significant role in the treatment of recurring or higher graded meningiomas [6] as well as meningiomas in difficult locations in elderly patients [15]. Besides several clinical studies, no medical treatment option was able to achieve a usable antitumor efficacy [5, 21]. Peptide receptor radionuclide therapy (PRRT), however, is a promising treatment option first established in gastrointestinal-pancreatic neuroendocrine tumors (GEP-NET) [24, 40]. Six different somatostatin receptor types (SSTR1, SSTR2A, SSTR2B, SSTR3, SSTR4, and SSTR5) have been detected in numerous different human tissues [30] as well as several tumor types [25, 39]. Tumors can express more than one SSTR. Such tumor tissue that expresses somatostatin receptors can be approached with radionuclide labeled somatostatin analogs [12, 41]. By itself, somatostatin is known to have antiproliferative and anti-angiogenic effects [31, 34]. Coupled with a radionuclide, somatostatin receptor expressing tumor tissue can be specifically targeted with no significant damage to normal tissue. This treatment concept has also been investigated in other tumor tissues [9], and clinical efficacy of PRRT in selected recurrent meningioma cases has been reported [4, 23, 27, 37].

Some studies have analyzed the distribution of somatostatin receptors in meningiomas, especially SSTR2A. However, the patient cohorts were small, mainly consisted of WHO grade I meningiomas, and the tumor grading in these studies deviates from the current WHO classification of central nervous system tumors in which CNS infiltration in meningiomas significantly influences the grading [2, 3, 11, 26, 31, 36, 38]. But especially patients with WHO grade II and III meningiomas and neurofibromatosis type 2 (NF2), who frequently develop many intracranial meningiomas [1], are subjects that need to be further assessed regarding this targeted therapy option. Therefore, we analyzed the distribution of 5 somatostatin receptors (SSTR1, SSTR2A, SSTR3, SSTR4, SSTR5) in a large meningioma cohort including patients suffering from NF2 and higher grade meningiomas, as well as meningiomas from patients suffering from neurofibromatosis type 2 that were treated between July 2003 and March 2017 were included in order to have larger subgroups of these less common patients that are potential candidates for PRRT. Overall, paraffin-embedded tumor tissue samples of 726 meningiomas were available and suitable for tissue microarray construction. Furthermore, the following clinical data was collected: age, gender, histopathological diagnosis (2016 WHO classification), presence of NF2, prior radiotherapy, primary or recurrent tumor, and tumor location.

Tissue microarray and immunohistochemistry

All meningiomas were histopathologically graded using the 2016 WHO classification for central nervous system tumors [26]. Provided by the Department of Neuropathology, paraffin-embedded tumor tissue samples were used for the construction of tissue microarrays. Representative areas for 1-mm tissue cylinder extraction were marked after histological evaluation of the corresponding hematoxylin eosin stain. A conventional tissue microarrayer was used (Beecher Instruments, Sun Prairie, Wisconsin, USA) to extract 2 sample cylinders from different tumor regions if enough representative tumor tissue was available, which was the case for most tumors. Via microtomy, 4-μm slices from the acceptor block were prepared, and after drying at 65°C for 15 min, immunohistochemical staining was performed with a Ventana BenchMark immunostainer (Ventana Medical Systems, Tucson, Arizona, USA). The OptiView method was applied. For SSTR1, pretreatment was done with protease for 4 min, for SSTR2A with CC2 for 32 min, and for SSTR3–5 with CC1 for 30 min. Primary antibodies were administered at 37°C for 40 min for SSTR1, for 120 min for SSTR2A, and for 32 min for SSTR3–5. The following dilutions were used: SSTR1, 1:3000 (Gramsch, Schwabhausen, Germany); SSTR2A, 1:500 (Dianova, Hamburg, Germany); SSTR3, 1:1000 (Abcam, Cambridge, UK); SSTR4, 1:1000 (Gentex, Zeeland, USA); and SSTR5, 1:100 (Abcam, Cambridge, UK). Antibodies were validated with pancreatic tissue slides which were used as separate controls.

Microscopic assessment and statistical methods

To determine the expression of SSTR1–5 with regard to intensity and quantity, an intensity distribution score was applied as described by Barresi et al. [3] (Table 1) as meningiomas exhibit a similar receptor density as gastrointestinal-pancreatic neuroendocrine tumors [30]. Microscopic assessment was done by two investigators, and in difficult cases, a rating consensus was reached between both.
investigators. Statistical analysis was done with JMP® Statistical Discovery Software, version 15.1.0 (Cary, NC: SAS Institute Inc.; 1989). The one-way ANOVA test was applied with a significance level of \( \alpha < 0.05 \). A classification and regression tree (CART) analysis was done for the identification of age cutoffs regarding maximum differences in somatostatin expression for all 5 markers.

Results

Cohort characteristics

Overall, the immunohistochemical results together with clinical data of 726 meningiomas were analyzed. Sixty-nine percent of the meningiomas were diagnosed in female patients (502/726), while 31% were male (224/726). The mean age was 56.7 years ranging from 8.3 to 89.9 years. With 85%, the majority of cases were primary meningiomas (613/726), whereas 15% were surgically resected for tumor recurrence (113/726). Eight percent of cases received prior radiotherapy (61/726); 90% of these cases were recurrent meningiomas (55/61). Seventy-three tumors were resected from NF2 patients (10%). The majority of tumors were skull base meningiomas (52%, 375/726), while 39% were localized at the convexity or falx (282/726) and 10% along the spine (69/726). Details are displayed in Table 2. According to the WHO classification of 2016, 81% were grade I meningiomas, 16% grade II, and 3% grade III. The distribution of histological subgroups is shown in Table 3.

General distribution of SSTR expression

After construction of tissue microarrays, microtomy, and staining, there were only a few cases lost for analysis. The reasons were insufficient tissue amount or staining for proper scoring due to tissue detachment in 19, 15, 13, 11, and 9 cases for SSTR1, 2A, 3, 4, and 5, respectively. All SSTR subtypes were expressed in meningiomas. Examples of the immunohistochemical staining in three cases is illustrated in Fig. 1. Cases with an expression score below 1 were graded as negative. Immunohistochemically negative cases were rare for SSTR1, 2A, and 5 (\( n = 14, 4, \) and 10 cases, respectively) but more common for SSTR3 and 4 (\( n = 250 \) and 108, respectively). The mean expression for SSTR1 and SSTR2A had the highest mean values (6.5 and 5.9, respectively), and the mean scores for SSTR3 and 4 were the lowest (2.2 and 2.7, respectively), while the mean expression score for SSTR5 was 4.8 (Fig. 2).

Gender and age

A gender difference in expression score was only observed for SSTR1 with a slightly higher mean score in meningiomas of female patients (6.7 compared to 6.2, \( p = 0.0269 \)). The age cutoffs determined by the CART analysis ranged from 34.5 to 72.5 years (Table 2) and with significantly higher expression scores for older patients for SSTR1, 2A, and 5 and vice versa for SSTR3 and 4 (Table 2).

Tumor localization

Somatostatin receptor expression scores varied between different tumor locations. Especially spinal meningiomas exhibited significantly higher expression scores for SSTR1, 4, and 5 and lower values for SSTR2A and 3, when compared to meningiomas of the skull base and the convexity/falx. This was most pronounced for SSTR1, where spinal meningiomas reached a mean score of 8.1, significantly higher compared to skull base and convexity/falx location (6.7 and 5.8, respectively, \( p < 0.0001 \)). While the expression of SSTR4 was generally low in meningiomas when compared to other SSTRs (see Fig. 2), spinal tumor location showed the highest expression score (\( p = 0.0062 \)). For SSTR5, the differences were more pronounced with 5.7 for spinal meningiomas, while skull base and convexity/falx locations reached a mean score of 4.5 and 4.9 (\( p < 0.0001 \)). The highest expression score for SSTR2A was seen for skull base meningiomas with 6.2 followed by convexity/falx and spinal location (5.6 and 4.9, respectively, \( p = 0.0003 \)). Skull base meningiomas also reached the highest score for SSTR3 (2.2), while spinal and convexity/falx tumors had similar low mean scores (1.7 each, \( p < 0.0001 \)). For details, see Table 2 and Fig. 3.

Recurrent and irradiated meningiomas

Meningiomas that were treated with radiotherapy before resection had significant lower scores for SSTR1 (5.4 compared to 6.6, \( p = 0.0007 \)) and SSTR5 (4.3 compared 4.9, \( p = 0.0340 \)), while expression of SSTR2A, 3, and 4 were
| Table 2  | Cohort characteristics and immunohistochemical distribution of somatostatin receptor expression (ANOVA) |
|----------|--------------------------------------------------------------------------------------------------|
|          | SSTR1 | SSTR2A | SSTR3 | SSTR4 | SSTR5 |
|          | N (%)  | Mean (95%CI) | p Value | Mean (95%CI) | p Value | Mean (95%CI) | p Value | Mean (95%CI) | p Value | Mean (95%CI) | p Value |
| Gender   |        |        |        |        |        |
| Female   | 502 (69.1) | 6.7 (6.4–6.9) | 0.0269* | 5.8 (5.5–6.0) | 0.2076 | 2.2 (2.0–2.4) | 0.4467 | 2.8 (2.7–3.0) | 0.0806 | 4.8 (4.7–5.0) | 0.9765 |
| Male     | 224 (30.9) | 6.2 (5.8–6.5) |        | 6.0 (5.7–6.4) |        | 2.3 (2.0–2.6) |        | 2.6 (2.4–2.8) |        | 4.8 (4.6–5.1) |        |
| Age (cutoff according to CART) |        |        |        |        |        |
| ≥ 41.91 years | 41.91 years | 34.47 years |        | 72.45 years |        | 42.98 years |        | 45.77 years |        |
| < 5.5 (5.0–6.0) | 6.7 (6.5–6.9) | <.0001* | 5.9 (5.7–6.1) | 0.0011* | 1.4 (1.0–1.8) | <.0001* | 2.6 (2.5–2.8) | 0.0005* | 5.0 (4.8–5.1) | 0.0002* |
| Recurrence |        |        |        |        |        |
| Primary  | 613 (84.4) | 6.7 (6.5–6.9) | <.0001* | 5.8 (5.6–6.0) | 0.3696 | 2.2 (2.0–2.3) | 0.3610 | 2.8 (2.6–2.9) | 0.2436 | 4.9 (4.7–5.0) | 0.1503 |
| Recurrence | 113 (15.6) | 5.5 (5.0–6.0) |        | 6.1 (5.6–6.5) |        | 2.4 (2.0–2.8) |        | 2.6 (2.3–2.9) |        | 4.6 (4.2–4.9) |        |
| Prior radiation |        |        |        |        |        |
| Yes 61 (8.4) | 5.4 (4.7–6.1) | 0.0007* | 6.1 (5.4–6.8) | 0.4835 | 2.1 (1.5–2.6) | 0.6414 | 2.4 (2.0–2.9) | 0.1291 | 4.3 (3.9–4.8) | 0.0340* |
| No 665 (91.6) | 6.6 (6.4–6.8) |        | 5.8 (5.6–6.0) |        | 2.2 (2.1–2.4) |        | 2.8 (2.7–2.9) |        | 4.9 (4.7–5.0) |        |
| NF2 |        |        |        |        |        |
| Yes 73 (10.1) | 4.6 (4.0–5.2) | <.0001* | 5.0 (4.4–5.6) | 0.0049* | 3.8 (3.3–4.3) | <.0001* | 3.6 (3.3–4.0) | <.0001* | 3.9 (3.5–4.3) | <.0001* |
| No 653 (90.0) | 6.7 (6.5–6.9) |        | 6.0 (5.8–6.2) |        | 2.0 (1.9–2.2) |        | 2.6 (2.5–2.8) |        | 5.0 (4.8–5.1) |        |
| Localization |        |        |        |        |        |
| Convexity/Falx 282 (38.8) | 5.8 (5.5–6.2) | <.0001* | 5.6 (5.3–5.9) | 0.003* | 1.7 (1.5–2.0) | <.0001* | 2.6 (2.4–2.8) | 0.0062* | 4.5 (4.3–4.7) | <.0001* |
| Skull base 375 (51.7) | 6.7 (6.5–7.0) |        | 6.2 (5.9–6.5) |        | 2.6 (2.4–2.9) |        | 2.8 (2.6–2.9) |        | 4.9 (4.7–5.1) |        |
| Spinal 69 (9.5) | 8.1 (7.5–8.8) |        | 4.9 (4.3–5.6) |        | 1.7 (1.2–2.2) |        | 3.3 (2.9–3.7) |        | 5.7 (5.2–6.1) |        |
| 2016 WHO classification |        |        |        |        |        |
| I 585 (80.6) | 6.8 (6.6–7.0) | <.0001* | 5.8 (5.5–6.0) | 0.0160* | 2.2 (2.0–2.4) | 0.8841 | 2.9 (2.7–3.0) | 0.0011* | 4.9 (4.7–5.0) | 0.0003* |
| II 118 (16.3) | 5.6 (5.1–6.1) |        | 6.5 (6.0–7.0) |        | 2.2 (1.8–2.6) |        | 2.4 (2.1–2.7) |        | 4.8 (4.4–5.1) |        |
| III 23 (3.2) | 4.6 (3.5–5.8) |        | 5.5 (4.4–6.5) |        | 2.0 (1.1–2.9) |        | 2.0 (1.3–2.6) |        | 3.3 (2.5–4.1) |        |

Abbreviations: SSTR somatostatin receptor, CI confidence interval, CART classification and regression tree, NF2 neurofibromatosis type 2, WHO World Health Organization, ANOVA analysis of variance; asterisk (*) presents statistically significant results.
similar to tumor tissue that did not receive radiotherapy. Recurrent meningiomas showed a significantly reduced expression for SSTR1 as well, when compared to primary meningiomas (5.5 vs. 6.7, \(p < 0.0001\)). For details, see Table 2 and Supplementary Figures S1 and S2.

**Neurofibromatosis type 2**

Some of the largest differences of SSTR expression were observed when comparing NF2 and sporadic meningioma tissue. The expression scores of SSTR1, 2A, and 5 were significantly lower in meningiomas of NF2 patients. The largest difference was seen in SSTR1 with NF2 tumors reaching a mean score of 4.6 compared to 6.7 of sporadic meningiomas (\(p < 0.0001\)). On the contrary, the analysis of SSTR3 and 4 expression showed higher mean scores in NF2 meningiomas. For details, see Table 2 and Fig. 4.

**WHO grade and histologic subtype**

Significant expression differences for WHO grades were seen for SSTR1, 2A, 4, and 5, while no differences were observed for SSTR3. For SSTR1 and 4, a gradual decrease of the mean expression score was seen between WHO grades I, II, and III (\(p < 0.0001\) and \(p = 0.0011\), respectively). The expression of SSTR2A was similar for grades I and III meningiomas, while grade II tumors revealed a higher mean expression score (\(p = 0.0160\)). Immunohistochemical staining for SSTR5 was scored similar for grade I and II tumors, and lower values were seen for grade III meningiomas (\(p = 0.0003\)). For details, see Table 2 and Fig. 5. Marked differences in expression scores between histologic subtypes were seen for all 5 SSTRs (Table 3). Several entities reached high expression scores for different markers. Secretory meningiomas were standing out with the highest mean expression score for SSTR1, 2A, and 3. Angiomatous meningiomas had also high scores for SSTR1 and 2 and the highest values for SSTR4 and 5. Among WHO grade II tumors, chordoid meningiomas had higher expression scores for SSTR1 and 2A compared to atypical meningiomas.

**Discussion**

Our results show clear distinctions of somatostatin receptor expression in meningioma subgroups. Especially, SSTR1, 2A, and 5 show high expression rates. Among clinical
subgroups, expression differences regarding tumor location, recurrent tumor, prior radiotherapy, neurofibromatosis type 2, and WHO grade were identified.

A deeper understanding of the distribution and role of somatostatin receptors in meningiomas is essential to further develop and refine a differentiated targeted application. Our

Fig. 1 Examples of the immunohistochemical expression of somatostatin receptor 1 (a–c), 2A (d–f), 3 (g–i), 4 (j–l), and 5 (m–o) in three meningiomas of different WHO grades. Scale bar 100 μm
study presents the largest analysis of somatostatin receptors in meningiomas. Prior studies have given first insights into the expression of SSTRs in small cohorts, ranging from 20 to 60 cases [2, 3, 11, 32, 36, 38], but most of them lacked significant subgroups that are potential recipients of a targeted peptide radio receptor therapy. Especially, patients suffering from recurrent or higher grade meningiomas as well as neurofibromatosis type 2, who often show multiple meningiomas, are in need of other treatment options. For example, one of the largest retrospective studies analyzed 60 meningiomas, including 11 grade II and 2 grade III tumors [38]. With over 100 meningiomas of higher WHO grade as well as large groups of tumors that received prior radiotherapy or have been resected from NF2 patients, we are able to describe the expression of somatostatin receptors in these highly relevant patient groups with marked differences that have the potential to be exploited for therapeutic purposes.

PRRT represents a promising therapy that has untapped potential in meningiomas. So far, only SSTR2A has been used as the target for PRRT, and its expression can be analyzed via PET imaging prior to treatment [18]. The intensity of the tracer uptake in the so-called DOTATAE/DOTATOC PET imaging can also predict the treatment response to SSTR2A-based PRRT [37] and outline residual or recurrent tumor tissue for further treatment planning [10]. With an integration of other somatostatin receptors into SSTR-PET imaging, this diagnostic tool could be further refined. The efficacy of PRRT has been shown in several studies with

Fig. 2 Distribution of the expression score of somatostatin receptors (a), 2A (b), 3 (c), 4 (d), and 5 (e). The y-axis presents the number of cases.
mostly small cohorts ranging from 10 to 20 patients [13, 19]. Higher immunohistochemical expression of SSTR2A in meningioma tissue prior to PRRT was associated with longer progression-free survival in a small retrospective analysis of 18 cases [37]. Although these retrospective studies are small and are composed of mostly recurrent and treatment-resistant, higher grade meningiomas, treatment efficacy was seen if high receptor expression was detected. With the new insights of our study, a more specific and patient-tailored treatment according to a multi receptor expression is possible.

For example, our data clearly show lower expression rates for SSTR1, 2A, and 5 in meningiomas from NF2 patients and increased scores for SSTR3 and 4. If these differences are associated with a lower efficacy of PRRT, which is currently administered SSTR2-specific, remains unclear. But it is possible that a substance with a multi receptor affinity may result in better therapy response. A similar argument can be made for spinal meningiomas that showed the lowest SSTR2A expression compared to other meningioma localizations but the highest for SSTR1, 4, and 5. Again, our results suggest that other PRRT substances could be more ideal for this tumor subgroup. It should be kept in mind that especially spinal meningiomas are less likely to recur or develop an aggressive behavior [14], thus making them not the classic subgroup for PRRT. Furthermore, skull base meningiomas are challenging to operate and are thus more likely to be subtotally resected. Meningiomas of this location reached the highest SSTR2A expression score, but also possessed high expressions of SSTR1 and 5, underlining the potential of a multi receptor target for PRRT.

Regarding histology, STR expression showed large variations. Secretory and angiomatous were among the highest SSTR expressing meningioma subtypes, making these entities especially interesting targets for PRRT. Furthermore, these entities are known for non-NF2 molecular alterations [8, 33]. However, meningiomas of higher WHO grade are more likely to reach a point where alternative therapy options like PRRT can be very helpful. Unfortunately, WHO grade III tumors in our cohort showed the lowest expression scores for all SSTRs. It can be argued that lower SSTR expression with higher WHO grade may be due to a dedifferentiation of meningiomas as has been suggested in regard to the loss of the expression

Fig. 3 SSTR expression in different meningioma localizations (a SSTR1, b SSTR2A, c SSTR3, d SSTR4, e SSTR5); asterisk (*) presents statistically significant results
of hormone receptors is higher grade meningiomas [20, 22]. Of course, this does not automatically suggest that these tumors should be precluded from PRRT. It rather stresses the need to develop multi affinity substances. Even for grade II meningiomas that show a high expression of SSTR2A, good expression was also seen for SSTR1 and 5, implying that PRRT targeting all SSTRs, but especially SSTR1, 2A, and 5, may be beneficial in delivering radiation to tumor cells more sufficiently.

Substances that target multiple somatostatin receptors with high affinity have been developed and evaluated for the treatment of neuroendocrine tumors and acromegaly [28]. Especially the new generation substance pasireotide has a high affinity to multiple SSTR receptors with a reported 39-fold affinity to SSTR5 compared to octreotide [28]. Furthermore, administering the long-acting somatostatin analog octreotide by itself has been shown to be efficacious in a subgroup of recurrent meningiomas with a partial radiographic response in 5 of 16 patients after 6 months [7]. A phase II clinical trial has demonstrated a positive response in a group of 20 recurrent meningiomas after administration of octreotide combined with the mTOR inhibitor everolimus [17]. However, the superior antiproliferative activity of pasireotide and especially decreased cell viability in combination with everolimus has been shown in vitro [16]. Overall, there is a lot of potential in the further development and refinement of PRRT to optimize the efficacy of this highly promising treatment approach. Our data demonstrate how differences in clinical subgroups could be utilized for a more tailored PRRT.

Furthermore, it is of interest to assess the response to PRRT depending on the immunohistochemical receptor expression. Although there are defined cutoffs for SSTR2-based PET imaging [37], it remains unclear what degree of immunohistochemical receptor expression may be sufficient for an efficacious PRRT. In addition to that, it is still unknown how the receptor expression may behave after radiotherapy or PRRT. These are questions we plan to address with future projects.
The main limitation of the presented study is its retrospective nature. Due to the expertise in skull base surgery and neurofibromatosis type 2, the cohort includes more meningiomas of the skull base as well as recurrent and NF2 associated tumors. Furthermore, the differences in SSTR expression are in some cases quite small, and it is unclear if this is associated with a difference in biology or response to PRRT. However, the goal of this study was the description of SSTR distribution and the comparison of clinical subgroups. The biological relevance of the different immunohistochemical SSTR expression levels will be the subject of further research efforts.

**Conclusion**

The expression of somatostatin receptors 1, 2A, 3, 4, and 5 in meningiomas shows differences between relevant clinical subgroups, especially recurrent or radiated tumors and meningiomas resected from NF2 patients. Overall, high expressions of SSTR1, 2A, and 5 were seen. Thus, a broader receptor affinity of substances used for peptide radioreceptor therapy has the potential to improve the treatment delivery in meningioma tissue.

**Supplementary Information** The online version contains supplementary material available at https://doi.org/10.1007/s10143-021-01552-y.

**Authors’ contributions** Conceptualization: F.B., S.C., G.T., J.H., M.T., and J.S. Methodology: F.B., C.F., and J.S. Software: F.B., C.F., and J.S. Validation: F.B., M.S., M.R., and J.S. Formal analysis: F.B., C.F., M.S., M.R., S.C., and J.S. Investigation: F.B.; resources: F.B., G.T., J.H., M.T., and J.S. Data curation: F.B. and C.F. Writing, original draft preparation: F.B. and C.F. Writing, original draft preparation: F.B., C.F., and J.S. Writing, review and editing: F.B., C.F., and J.S. Visualization: C.F. and J.S. Supervision: C.F. and J.S. Project administration: F.B. and J.S. All authors have read and agreed to the published version of the manuscript.

**Funding** Open Access funding enabled and organized by Projekt DEAL.

**Data availability** The dataset is available upon reasonable request.

**Code availability** No applicable.
Declarations

Ethics approval  The study was approved by the Clinical Ethics Committee of the University of Tübingen (Project number: 618/2014BO2).

Consent to participate  Tumor tissue and clinical data were only used if patient consent was available as defined by the Clinical Ethics Committee of the University of Tübingen.

Consent for publication  Not applicable.

Conflict of interest  The authors declare no competing interests.

Open Access  This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Ardern-Holmes S, Fisher G, North K (2017) Neurofibromatosis Type 2. J Child Neurol 32:9–22. https://doi.org/10.1177/0883073816666736
2. Arena S, Barbieri F, Thellung S, Pirani P, Corsaro A, Villa V, Dadati P, Dorcaratto A, Lapertosa G, Ravetti JL, Spaziante R, Schettini G, Florio T (2004) Expression of somatostatin receptor mRNA in human meningiomas and their implication in vitro antiproliferative activity. J Neurooncol 66:155–166. https://doi.org/10.1023/b:neon.0000013498.19981.55
3. Barresi V, Alafaci C, Salpietto F, Tuccari G (2008) Sstr2A immunohistochemical expression in human meningiomas: is there a correlation with the histological grade, proliferation or microves‑sel density? Oncol Rep 20:485–492.
4. Bartolomei M, Bodei L, De Cicco C, Grana CM, Cremonesi M, Botteri E, Baio SM, Arico D, Sansovini M, Paganelli G (2009) Peptide receptor radionuclide therapy with (90)Y-DOTATOC in recurrent meningioma. Eur J Nucl Med Mol Imaging 36:1407–1416. https://doi.org/10.1007/s00259-009-1115-z
5. Brastianos PK, Galanis E, Butowski N, Chan JW, Dunn IF, Gold‑brunner R, Herold-Mende C, Ippen FM, Mawrin C, McDermott MW, Sloan A, Snyder J, Tabatabai G, Tatagiba M, Tonn JC, Wen PY, Aldape K, Nissiri F, Zadeh G, Jenkinson MD, Raleigh DR, International Consortium on M (2019) Advances in multidisciplinary therapy for meningiomas. Neuro Oncol 21:i18–i31. https://doi.org/10.1093/neuonc/noy136
6. Buglione M, De Bari B, Trevisan F, Ghirardelli P, Pedretti S, Trig‑giani L, Magrini SM (2014) Role of external beam radiotherapy in the treatment of relapsing meningioma. Med Oncol 31:866. https://doi.org/10.1007/s12032-014-0886-y
7. Chamberlain MC, Giangt MJ, Fadal CE (2007) Recurrent meningioma: salvage therapy with long‑acting somatostatin analogue. Neurology 69:969–973. https://doi.org/10.1212/01.wnl.0000271382.62776.b7
8. Clark VE, Erson-Omay EZ, Serin A, Yin J, Cotney J, Ozduman K, Avsar T, Li J, Murray PB, Henegarau O, Yilmaz S, Gunel JM, Carrion-Grant G, Yilmaz B, Grady C, Tanrikulu B, Bakircio glu M, Kaymakcalan H, Caglayan AO, Sencar L, Ceyhun E, Atik AF, Bayri Y, Bai H, Kolb LE, Hebert RM, Omay SB, Mishra‑Goruk K, Choi M, Overton JD, Holland EC, Mane S, State MW, Bilguvar K, Baehrning JM, Gutin PH, Piepmeier JM, Vortmeyer A, Brennan CW, Pamir MN, Kilic T, Lifton RP, Noonan JP, Yusuno K, Gunel M (2013) Genomic analysis of non‑NF2 meningiomas reveals mutations in TRAF7, KLF4, AKT1, and SMO. Science 339:1077–1080. https://doi.org/10.1126/science.1233009
9. Dash A, Chakraborty S, Pillai MR, Knapp FF Jr (2015) Peptide receptor radionuclide therapy: an overview. Cancer Biother Radi‑o pharm 30:47–71. https://doi.org/10.1098/cbr.2014.1741
10. Dressen MS, Muthukrishnan A, Tragon TR, Lieberman FS, Moutz J (2019) Complementary molecular and metabolic char‑acterization of meningiomas with DOTATATE and FDG‑PET: advancing treatment planning and prognostication. Clin Nucl Med 44:e26–e27. https://doi.org/10.1097/RLU.0000000000002328
11. Doutur A, Kumar U, Panetta R, Ouafik L, Fina F, Sasi R, Patel YC (1998) Expression of somatostatin receptor subtypes in human brain tumors. Int J Cancer 76:620–627.
12. Froidevaux S, Eberle AN (2002) Somatostatin analogs and radio‑peptides in cancer therapy. Biopolymers 66:161–183. https://doi. org/10.1002/bip.10256
13. Gerster-Gillieron K, Forrer F, Maecke H, Mueller-Brand J, Merlo A, Cordier D (2015) 90Y-DOTATOC as a therapeutic option for complex recurrent or progressive meningiomas. J Nucl Med 56:1748–1751. https://doi.org/10.2967/jnumed.115.155853
14. Gilard V, Goia A, Ferracci FX, Marguet F, Magne N, Langlois O, Perez A, Derrey S (2018) Spinal meningioma and factors predic‑tive of post‑operative deterioration. J Neurooncol 140:49–54. https://doi.org/10.1007/s11060-018-2929-y
15. Goldbrunner R, Minniti G, Preusser M, Jenkinsn MD, Salla‑banda K, Houdart E, van Deimling A, Stavrinou P, Lefranc F, Lund-Johansen M, Moyal EC, Brandsma D, Henriksson R, Sof‑etti R, Weller M (2016) EANO guidelines for the diagnosis and treatment of meningiomas. Lancet Oncol 17:e383‑391. https://doi.org/10.1016/S1470-2045(16)30321-7
16. Graillon T, Romano D, Delilles C, Lisbonis C, Saveanu A, Fig‑arella-Branger D, Roche PH, Fuentes S, Chinot O, Dufour H, Bar‑lier A (2017) Pasireotide is more effective than octreotide, alone or combined with everolimus on human meningioma in vitro. Oncotarget 8:55361–55373. https://doi.org/10.18632/oncotarget.19517
17. Graillon T, Sanson M, Cappello C, Idbaix A, Peyre M, Peyriere H, Basset N, Autran D, Roche K, Calamidares M, Roche PH, Fuentes S, Tabouret E, Barrie M, Cohen A, Honore S, Bouckeine M, Baumstarck K, Figarella-Branger D, Barlier A, Dufour H, Chinot OL (2020) Everolimus and octreotide for patients with recurrent meningioma: results from the phase II CEVOREM trial. Clin Cancer Res 26:552–557. https://doi.org/10.1158/1078-0432.CCR-19-2109
18. Hanescheid H, Sweeney RA, Flentje M, Buck AK, Lohr M, Sam‑nick S, Kreissl M, Verbarg FA (2012) PET SUV correlates with radionuclide uptake in peptide receptor therapy in meningioma. Eur J Nucl Med Mol Imaging 39:1284–1288. https://doi.org/10.1007/s00259-012-1214-x
19. Hartmann PE, Hanescheid H, Kertels O, Schirbel A, Kreissl MC, Flentje M, Sweeney RA, Buck AK, Polat B, Lapa C (2020) Long‑term results of multimodal peptide receptor radionuclide therapy and fractionated external beam radiotherapy for treatment of advanced symptomatic meningioma. Clin Transl Radiat Oncol 22:29–32. https://doi.org/10.1016/j.cstr.2020.03.002
20. Hsu DW, Efird JT, Hedley-Whyte ET (1997) Progesterone and estrogen receptors in meningiomas: prognostic considerations. J Neurosurg 86:113–120. https://doi.org/10.3171/jns.1997.86.1.0113
21. Karsy M, Guan J, Cohen A, Colman H, Jensen RL (2016) Medical management of meningiomas: current status, failed treatments, and promising horizons. Neurosurg Clin N Am 27:249–260. https://doi.org/10.1016/j.nec.2015.11.002

22. Konstantinidou AE, Korkolopoulou P, Mahera H, Kotsiakos X, Hraniotis S, Efthydiadis C, Patsours E (2003) Hormone receptors in non-malignant meningiomas correlate with apoptosis, cell proliferation and recurrence-free survival. Histopathology 43:280–290. https://doi.org/10.1046/j.1365-2559.2003.01712.x

23. Kreissl MC, Hanscheid H, Lohr M, Verbarg FA, Schiller M, Lassmann M, Reiners C, Sannick SS, Buck AK, Flemtje M, Sweeney RA (2012) Combination of peptide receptor radionuclide therapy with fractionated external beam radiotherapy for treatment of advanced symptomatic meningioma. Radiat Oncol 7:99. https://doi.org/10.1186/1748-717X-7-99

24. Kwkkeboom DJ, de Herder WW, Kam BL, van Eijck CH, van Essen M, Kooij PP, Feelders RA, van Aken MO, Krenning EP (2008) Treatment with the radiolabeled somatostatin analog [177Lu-DOTA 0, Tyr3]octreotate: toxicity, efficacy, and survival. J Clin Oncol 26:2124–2130. https://doi.org/10.1200/JCO.2007.15.2553

25. Lamberts SW, Krenning EP, Reubi JC (1991) The role of somatostatin and its analogs in the diagnosis and treatment of tumors. Endocr Rev 12:450–482. https://doi.org/10.1210/edrv-12-4-450

26. Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, Ohgaki H, Wiestler OD, Kleihues P, Ellison DW (2016) The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol 131:803–820. https://doi.org/10.1007/s00401-016-1545-1

27. Minuti F, Amato E, Sindoni A, Cardile D, Conti A, Herberg A, Baldari S (2014) Peptide receptor radionuclide therapy in patients with inoperable meningiomas: our experience and review of the literature. Cancer Biother Radiopharm 29:193–199. https://doi.org/10.1089/cbr.2013.1599

28. Oberg K, Lamberts SW (2016) Somatostatin analogues in acromegaly and gastroenteropancreatic neuroendocrine tumours: past, present and future. Endocr Relat Cancer 23:R551–R566. https://doi.org/10.1530/ERC-16-0151

29. Ostrom QT, Cioffi G, Gittleman H, Patil N, Waite K, Krucho K, Barnholtz-Sloan JS (2019) CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2012–2016. Neuro Oncol 21:v1–v100. https://doi.org/10.1093/neuonc/noz150

30. Reubi JC (2004) Somatostatin and other Peptide receptors as tools for tumor diagnosis and treatment. Neuroendocrinology 80(Suppl 1):51–56. https://doi.org/10.1159/000080742

31. Reubi JC, Laisse JA (1995) Multiple actions of somatostatin in neoplastic disease. Trends Pharmacol Sci 16:110–115. https://doi.org/10.1016/s0165-6147(00)88992-0

32. Reubi JC, Kappeler A, Waser B, Laisse J, Hipkin RW, Schonbrunn A (1998) Immunohistochemical localization of somatostatin receptors sst2A in human tumors. Am J Pathol 153:233–245. https://doi.org/10.1016/S0002-9440(94)85564-2

33. Reuss DE, Piro RM, Jones DT, Simon M, Ketter R, Kool M, Becker A, Sahm F, Pusch S, Meyer J, Hagenlocher C, Schweizer L, Capper D, Kickingereder P, Mucha J, Koelsche C, Jager N, Santarius T, Tarpey PS, Stephens PJ, Andrew Futreal P, Wellenreuther R, Kraus J, Lenartz D, Herold-Mende C, Hartmann C, Mawrin C, Giese N, Eils R, Collins VP, Konig R, Wiestler OD, Pfister SM, von Deimling A (2013) Secretory meningiomas are defined by combined KLF4 K409Q and TRAF7 mutations. Acta Neuropathol 125:351–358. https://doi.org/10.1007/s00401-013-1093-x

34. Ribatti D, Conconi MT, Nussdorfer GG (2007) Nonclassic endogenous novel [corrected] regulators of angiogenesis. Pharmacol Rev 59:185–205. https://doi.org/10.1124/pr.59.2.3

35. Rogers L, Barani I, Chamberlain M, Kaley TJ, McDermott M, Raizer J, Schaff D, Weber DC, Wen PY, Vogelbaum MA (2015) Meningiomas: knowledge base, treatment outcomes, and uncertainties. A RANO review. J Neurosurg 122:4–23. https://doi.org/10.3171/2014.7.JNS131644

36. Schlutz S, Pauli SU, Schulz S, Handel M, Dietzmann K, Firsching R, Holtt V (2000) Immunohistochemical determination of five somatostatin receptors in meningioma reveals frequent overexpression of somatostatin receptor subtype sst2A. Clin Cancer Res 6:1865–1874

37. Seystahl K, Stoecklein V, Schuller U, Rushing E, Nicolas G, Schafer N, Ilhan H, Pangalu A, Weller M, Tonon JC, Sommerauer M, Albert NL (2016) Somatostatin receptor-targeted radionuclide therapy for progressive meningioma: benefit linked to 68Ga-DOTATATE/TODC uptake. Neuro Oncol 18:1538–1547. https://doi.org/10.1093/neuonc/nox060

38. Silva CB, Ongaratti BR, Trott G, Haag T, Ferreira NP, Leaes CG, Pereira-Lima JF, Oliveira Mda C (2015) Expression of somatostatin receptors (SSTR1–SSTR5) in meningiomas and its clinicopathological significance. Int J Clin Exp Pathol 8:13815–13929

39. Theodoropoulou M, Stallia GK (2013) Somatostatin receptors: from signaling to clinical practice. Front Neuroendocrinol 34:228–252. https://doi.org/10.1016/j.yfrne.2013.07.005

40. van der Zwan WA, Bodei L, Mueller-Brand J, de Herder WW, Kvols LK, Kwkkeboom DJ (2015) GEPNETs update: radionuclide therapy in neuroendocrine tumors. Eur J Endocrinol 172:R1–8. https://doi.org/10.1530/EJE-14-0488

41. Virgolini I, Traub T, Novotny C, Leimer M, Fuger B, Li SR, Patri P, Pangerl T, Angelberger P, Raderer M, Burggass G, Andrease F, Kurtaran A, Dudevck R (2002) Experience with indium-111 and yttrium-90-labeled somatostatin analogs. Curr Pharm Des 8:1781–1807. https://doi.org/10.2174/138161202393756

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.